Material Weakness (worsened) — Control deficiencies now span three consecutive audit periods (2023-2025) with no successful remediation despite ongoing efforts.
Delisting (removed) — Nasdaq minimum market value deficiency disclosed in prior quarter with November 2025 deadline no longer mentioned, suggesting compliance regained or deadline passed without action.

NASDAQ: CLNN Clene Inc. 10-Q

Clene advances toward ALS drug filing but burns cash faster; material control weaknesses persist

Filed May 14, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 7, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade CLNN commission-free

Open an account, get a free stock.

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 1, 2026 5:03 PM